{"entity":{"id":"hofman-michael","kind":"person","name":"Michael Hofman","aka":[],"tldr":"Led proPSMA and TheraP, the trials that proved PSMA PET beats conventional imaging and that lutetium-PSMA beats chemotherapy.","summary":"Michael Hofman is Professor of Nuclear Medicine and Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence at the Peter MacCallum Cancer Centre in Melbourne. He led proPSMA, which proved that PSMA PET-CT beats conventional imaging for staging high-risk prostate cancer before curative-intent surgery or radiotherapy, and TheraP, the ANZUP trial that showed lutetium-177 PSMA-617 beats cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer. His publications include the proPSMA and TheraP reports, and his trials made Australia a global centre of theranostics. He now leads trials of earlier-line and combination radioligand therapy.","asOf":"2026-09-08","links":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hofman%20MS%5BAuthor%5D%20PSMA"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":["propsma","therap"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Nuclear Medicine; Director, Prostate Cancer Theranostics and Imaging Centre of Excellence","institutionId":"peter-mac","specialisms":["Theranostics","PSMA PET","Lutetium-PSMA therapy","Nuclear medicine"],"profiles":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hofman%20MS%5BAuthor%5D%20PSMA"}],"papers":[{"title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA)","journal":"Lancet","year":2020,"doi":"10.1016/S0140-6736(20)30314-7"},{"title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP)","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)00237-3"}],"orcid":"0000-0001-8622-159X"},"route":"/people/hofman-michael/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"drug":[{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"institution":[{"id":"movember","kind":"institution","name":"Movember","route":"/institutions/movember/"},{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/"}],"trial":[{"id":"propsma","kind":"trial","name":"proPSMA","route":"/trials/propsma/"},{"id":"therap","kind":"trial","name":"TheraP (ANZUP 1603)","route":"/trials/therap/"}],"idea":[{"id":"idea-fund-academic-radiopharma-pipeline","kind":"idea","name":"A university cyclotron network with shared regulatory files for new tracers","route":"/ideas/idea-fund-academic-radiopharma-pipeline/"}],"company":[{"id":"anzup","kind":"company","name":"ANZUP Cancer Trials Group","route":"/companies/anzup/"}]}}